{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:04:15Z","timestamp":1782727455566,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.hfc.2022.03.008","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T19:19:11Z","timestamp":1665170351000},"page":"645-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk"],"prefix":"10.1016","volume":"18","author":[{"given":"Clare","family":"Arnott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.hfc.2022.03.008_bib1","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes","year":"2018","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.hfc.2022.03.008_bib2","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.2337\/dc19-S001","article-title":"1. Improving care and promoting health in populations: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.hfc.2022.03.008_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"issue":"21","key":"10.1016\/j.hfc.2022.03.008_bib4","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2022.03.008_bib5","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"10","author":"Wiviott","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hfc.2022.03.008_bib6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2022.03.008_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hfc.2022.03.008_bib8","doi-asserted-by":"crossref","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","article-title":"Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"9","author":"Arnott","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.hfc.2022.03.008_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1016\/j.hfc.2022.03.008_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hfc.2022.03.008_bib11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.hfc.2022.03.008_bib12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.hfc.2022.03.008_bib13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2022.03.008_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijcard.2020.09.050","article-title":"An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials","volume":"324","author":"Yu","year":"2021","journal-title":"Int J Cardiol"},{"issue":"10166","key":"10.1016\/j.hfc.2022.03.008_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.hfc.2022.03.008_bib16","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes","year":"2020","journal-title":"Diabetes Care"},{"issue":"36","key":"10.1016\/j.hfc.2022.03.008_bib17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2022.03.008_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12882-021-02381-3","article-title":"Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study","volume":"22","author":"Jeong","year":"2021","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1016\/j.hfc.2022.03.008_bib19","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/dom.14091","article-title":"The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial","volume":"22","author":"Arnott","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"10.1016\/j.hfc.2022.03.008_bib20","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2022.03.008_bib21","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.hfc.2022.03.008_bib22","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"10.1016\/j.hfc.2022.03.008_bib23","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.hfc.2022.03.008_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2022.03.008_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.hfc.2022.03.008_bib26","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hfc.2022.03.008_bib27","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","article-title":"Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease","volume":"40","author":"Barnes","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.hfc.2022.03.008_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","article-title":"SGLT2 inhibitors and lower limb complications: an updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.hfc.2022.03.008_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00125-019-4835-z","article-title":"Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use","volume":"62","author":"Potier","year":"2019","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.hfc.2022.03.008_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jacbts.2018.01.010","article-title":"Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia","volume":"3","author":"Sherman","year":"2018","journal-title":"JACC Basic Transl Sci"},{"issue":"10","key":"10.1016\/j.hfc.2022.03.008_bib31","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00125-019-4955-5","article-title":"Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS program","volume":"62","author":"Zhou","year":"2019","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.hfc.2022.03.008_bib32","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/jbmr.1759","article-title":"Type 2 diabetes and bone","volume":"27","author":"Leslie","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.hfc.2022.03.008_bib33","first-page":"653","article-title":"Evaluation of fracture risk in chronic kidney disease","volume":"30","author":"Torres","year":"2017","journal-title":"J\u00a0Nephrol"},{"issue":"1","key":"10.1016\/j.hfc.2022.03.008_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/00325481.2017.1256747","article-title":"Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus","volume":"129","author":"Blevins","year":"2017","journal-title":"Postgrad Med"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:41:48Z","timestamp":1761554508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713622000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1551713622000332"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2022.03.008","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2022.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}